Berotralstat
Sponsors
Biocryst Pharmaceuticals Inc., BioCryst Pharmaceuticals
Conditions
HAEHereditary AngioedemaHereditary Angioedema (HAE)PediatricProphylaxis
Phase 3
Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
Enrolling by invitationNCT04933721
Start: 2021-07-23End: 2031-08-31Target: 139Updated: 2025-12-23
Berotralstat Treatment in Children With Hereditary Angioedema
Active, not recruitingNCT05453968
Start: 2022-10-25End: 2027-02-01Updated: 2026-02-25
An open-label study to provide berotralstat access to subjects with type I and II hereditary angioedema who were previously enrolled in berotralstat studies
Active, not recruitingCTIS2024-511285-37-00
Start: 2021-08-31Target: 47Updated: 2025-10-22
An open-label study to provide berotralstat access to subjects with type I and II hereditary angioedema who were previously enrolled in berotralstat studies
Active, not recruitingCTIS2024-511285-37-00
Start: 2021-08-31Target: 47Updated: 2025-10-22
A Phase 3 Study to Evaluate the Safety and Pharmacokinetics of Berotralstat Prophylaxis in Children with Hereditary Angioedema (HAE) Who Are 2 To < 12 Years of Age.
Active, not recruitingCTIS2024-511257-22-00
Start: 2022-10-13Target: 19Updated: 2025-09-29